1. Home
  2. ESAB vs IRTC Comparison

ESAB vs IRTC Comparison

Compare ESAB & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ESAB Corporation

ESAB

ESAB Corporation

N/A

Current Price

$108.16

Market Cap

8.1B

Sector

Industrials

ML Signal

N/A

Logo iRhythm Technologies Inc.

IRTC

iRhythm Technologies Inc.

N/A

Current Price

$119.72

Market Cap

4.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ESAB
IRTC
Founded
1904
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Office Equipment/Supplies/Services
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.1B
4.8B
IPO Year
2022
2016

Fundamental Metrics

Financial Performance
Metric
ESAB
IRTC
Price
$108.16
$119.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
13
Target Price
$144.13
$209.69
AVG Volume (30 Days)
357.8K
619.9K
Earning Date
05-25-2026
05-25-2026
Dividend Yield
0.37%
N/A
EPS Growth
N/A
61.71
EPS
3.67
N/A
Revenue
$2,842,555,000.00
$747,138,000.00
Revenue This Year
$6.42
$19.58
Revenue Next Year
$5.59
$15.95
P/E Ratio
$29.43
N/A
Revenue Growth
3.71
26.24
52 Week Low
$100.17
$92.52
52 Week High
$137.42
$210.01

Technical Indicators

Market Signals
Indicator
ESAB
IRTC
Relative Strength Index (RSI) 29.84 29.44
Support Level N/A $119.48
Resistance Level $118.33 $167.19
Average True Range (ATR) 4.28 6.99
MACD -2.41 -1.04
Stochastic Oscillator 12.61 2.67

Price Performance

Historical Comparison
ESAB
IRTC

About ESAB ESAB Corporation

ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.7 billion in revenue in 2024.

About IRTC iRhythm Technologies Inc.

iRhythm Holdings Inc formerly, iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.

Share on Social Networks: